Tilray Brands, Inc. (TLRY)
BrewDog Acquisition Boosts Tilray's Q1 Performance
Tilray reported Q1-2027 financial results last week with increasing revenue from its BrewDog operations; Cannabis revenue decreased. The company expects its new beer assets along with its international cannabis operations to continue to drive growth. The company reported a net loss and negative free cash flow.
Tilray Q1: Not Looking Good, Remains A 'Hold'
Tilray reported disappointing fiscal Q1 results, missing revenue estimates despite management highlighting record sales. TLRY's revenue growth was driven solely by the BrewDog acquisition; core cannabis sales declined 13%, and the adjusted bottom line swung to a loss. Cash burn surged to $23.4 million, and share dilution remains severe, with shares outstanding up over 31% year-over-year.
Tilray Brands, Inc. (TLRY) Q1 2027 Earnings Call Transcript
Tilray Brands, Inc. (TLRY) Q1 2027 Earnings Call Transcript
Tilray Brands Q1 Earnings Call Highlights
Tilray Brands NASDAQ: TLRY reported record first-quarter revenue and gross profit, driven by its BrewDog acquisition, international cannabis growth and pharmaceutical distribution operations, while reaffirming fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million.
Tilray revenue rises as beverage business drives record quarterly sales
Tilray Inc (NASDAQ:TLRY), the cannabis and consumer products company, reported record first-quarter revenue of $257.1 million, up 23% from a year earlier, driven by strong growth in beverages and international markets. Gross profit rose 35% to $77.5 million, while gross margin expanded to 30% from 27%, as the company continued to improve profitability across its businesses.
Tilray Brands, Inc. (TLRY) Reports Q1 Loss, Misses Revenue Estimates
Tilray Brands, Inc. (TLRY) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to break-even earnings per share a year ago.
Tilray Brands stock analysis ahead of earnings: will it rebound or fall further?
Tilray Brands (TLRY) has been in a strong downtrend and is now trading near its all-time low. The stock peaked at $4.94 in August and has since pulled back to $3.74.
Tilray stock has slumped 55% this year: is it a golden opportunity to buy?
Tilray Brands stock has remained under pressure and is underperforming the market this year. TLRY was trading at $4.15 after falling by 55% since January and by 62% in the last 12 months.
Tilray Brands, Inc. (TLRY) Gains As Market Dips: What You Should Know
Tilray Brands, Inc. (TLRY) closed at $4.14 in the latest trading session, marking a +2.99% move from the prior day.
Tilray Trades Below $5 With Record Fiscal Revenue on the Books. What's Holding the Stock Back?
Shares of Tilray Brands have fallen roughly 50% so far in 2026. The company's business posted record revenues and gross profit in fiscal 2026.
TLRY Stock Loses 17% in Three Months: Should You Buy, Hold or Sell?
Tilray's revenues and EBITDA are growing, but weak margins, negative cash flow and competition raise questions about its next move.
Tilray: Schedule III Is Moving Forward, And The Stock Is Still Cheap
Tilray Brands, Inc. remains a Buy as international medical cannabis revenue grew 34% and regulatory progress in the U.S. has advanced. TLRY's international cannabis business is now the primary growth driver, with strong gains in Germany, UK, Poland, and Italy despite price compression. GAAP profitability and free cash flow are still lacking, and dilution remains a concern, but underlying cash generation is improving.
